Immunovative Therapies Ltd.

Our living immune cells are "off-the-shelf" and uniquely provide a customized immune response to each individual. Our novel Mirror Effect® technology platform and products are protected by over 200 issued patents worldwide. Our lead product, AlloStim®, is now entering late stage clinical development and we are preparing the manufacturing infrastructure necessary for commercialization. Immunotherapy of cancer, also called immuno-oncology, is a form of cancer treatment that is designed to harness the power of the body’s own immune system to control and eliminate cancer. Our next generation Mirror Effect® technology provides solutions to these problems, broaden the indications that can respond to immunotherapy, significantly lower the cost and significantly reduce the side-effects. Our Mirror Effect® technology platform provides unprecedented capability to re-program immune responses that can be directed to treat or prevent cancer and viral pathogens, as well to remodel immune systems of the elderly to assure high quality of life as we age. A cloud-based centralized control over portable manufacturing pods, including an automated, closed, sterile “plug-and-play” cell processing system, an “artificial lymph node” high density bioreactor and horizontally-integrated supply chain of reagents, disposables and media formulations, for the economical, large-scale commercial manufacturing, formulation and distribution of living cell products.